11th Jul 2016 10:14
LONDON (Alliance News) - Onzima Ventures PLC Monday said that its 49%-owned investee company N4 Pharma Ltd has filed 17 patents for the reformulation of losartan, and 12 patents for the reformulation of valsartan.
Onzima said this was in line with N4's strategy of filing strong broad patents for a range of drugs it wishes to consider reformulating, and are part of the suite of patents it acquired from OPAL IP Ltd.
"These are the first of a range of other reformulation patents we intend to file for a number of existing generic or soon to be generic drugs in addition to those already filed for sildenafil," said N4 Chief Executive Officer Nigel Theobald in a statement.
"We will continue to file strong life cycle management patents for a range of drugs over the coming weeks and months. Our initial formulation focus is still on our work for sildenafil and we are now working with clinicians and formulators to decide which of these additional new drugs we will start reformulation work on next," Theobald added.
Shares in Onzima were down 1.0% at 1.56 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ONZ.L